Polyvinyl alcohol embolization microsphere as well as preparation method and application thereof

Through the grafting reaction of high-polymerization and low-polymerization polyvinyl alcohol and the cross-linking of ionic functional groups, a dense spherical shell is formed, which solves the problem of unstable polyvinyl alcohol microsphere strength and drug release rate, and improves drug delivery Efficiency and safety.

CN118924698APending Publication Date: 2024-11-12CARDIOLINK SCI (SHENZHEN) MEDICAL TECH DEV CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411319505.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing polyvinyl alcohol embolized microspheres introduce additional crosslinking structures during the preparation process, resulting in poorer microsphere strength and elasticity, prone to rupture, and unstable drug release rate, which poses clinical potential.

Method used

By grafting reactions using high-polymerization and low-polymerization polyvinyl alcohol, an interpenetrating network structure is formed and cross-linked with water-soluble monomers with ionic functional groups to form a dense polymer spherical shell to control the drug release rate.

Benefits of technology

It improves the mechanical properties of microspheres and drug sustained release properties, reduces drug leakage, achieves fine control of drug release rate, and enhances the efficiency and safety of drug delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924698A_ABST
    Figure CN118924698A_ABST
Patent Text Reader

Abstract

The invention relates to polyvinyl alcohol embolism microspheres as well as a preparation method and application thereof, and belongs to the technical field of embolism microspheres. The preparation method comprises the following steps: carrying out grafting reaction on high-polymerization-degree polyvinyl alcohol, low-polymerization-degree polyvinyl alcohol and a water-soluble cross-linking agent to obtain a macromonomer solution; wherein the polymerization degree of the high-polymerization-degree polyvinyl alcohol is 1700-2600, and the polymerization degree of the low-polymerization-degree polyvinyl alcohol is 300-500; adding the macromonomer solution, a water-soluble monomer with an ionic functional group and an initiator into water, and mixing to obtain a water phase; mixing an oil-soluble dispersing agent and an oil-soluble solvent to obtain an oil phase; and adding the water phase into the oil phase to form a water-in-oil reversed-phase suspension polymerization system, and carrying out reversed-phase suspension polymerization reaction to obtain the polyvinyl alcohol embolization microspheres. The polyvinyl alcohol embolization microsphere prepared by the preparation method has excellent strength and drug sustained release performance, and can be effectively used as a drug delivery carrier.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of embolic microspheres, and in particular to polyvinyl alcohol embolic microspheres and a preparation method and application thereof. Background Art

[0002] Polyvinyl alcohol is widely used in the preparation of drug carriers due to its excellent specific surface area effect and a large number of hydroxyl groups that can be used for modification. In the field of drug delivery, the common preparation methods of polyvinyl alcohol embolic microspheres include: reacting aminoacetaldehyde dimethyl acetal with acryloyl chloride to obtain N-acrylamidoacetaldehyde dimethyl acetal (NAAADA), and then reacting it with polyvinyl alcohol (PVA) in an acidic medium to produce PVA macromonomer (PVA-NAAADA), and using PVA-NAAADA and 2-acrylamide-2-methylpropanesulfonic acid (AMPS) as comonomers to prepare polyvinyl alcohol embolic microspheres by reverse suspension method. In this preparation method, due to the introduction of additional cross-linking structures during the polyvinyl alcohol modification process, the flexibility of the polyvinyl alcohol main chain is reduced, which leads to brittle structure, poor microsphere strength and elasticity, and easy rupture of microspheres during microsphere particle size screening and transcatheter injection. The microsphere fragments produced after crushing are difficult to remove due to their small particle size and good suspension. If used directly, it is easy to cause terminal vascular thrombosis and drug leakage, which poses a great clinical risk. In addition, since the drug-loaded microspheres mainly rely on the ion exchange mechanism to release drugs, affected by the initial release effect and drug saturation, when the microspheres first come into contact with the release medium (such as body fluids), the drug molecules will quickly exchange with the cationic groups on the surface of the microspheres, resulting in a faster drug release rate, which leads to a higher initial drug release concentration and unstable subsequent release rate. Summary of the invention

[0003] In order to solve the above technical problems, the purpose of the embodiments of the present application includes providing a polyvinyl alcohol embolic microsphere and a preparation method thereof, wherein the preparation method can improve the strength and sustained-release performance of the polyvinyl alcohol embolic microsphere.

[0004] In a first aspect, the present application provides a method for preparing polyvinyl alcohol embolic microspheres, comprising the following steps:

[0005] Preparing a macromolecular monomer solution: performing a grafting reaction on high-polymerization degree polyvinyl alcohol, low-polymerization degree polyvinyl alcohol and a water-soluble crosslinking agent in a certain proportion to obtain a macromolecular monomer solution; wherein the polymerization degree of the high-polymerization degree polyvinyl alcohol is 1700-2600, and the polymerization degree of the low-polymerization degree polyvinyl alcohol is 300-500;

[0006] Preparing the aqueous phase: adding the macromolecular monomer solution, the water-soluble monomer with ionic functional groups and the initiator into water, and mixing them to obtain the aqueous phase;

[0007] Preparing the oil phase: mixing the oil-soluble dispersant and the oil-soluble solvent to obtain the oil phase;

[0008] Reverse suspension polymerization: Add the water phase into the oil phase to form an oil-in-water reverse suspension polymerization system, and perform reverse suspension polymerization to obtain polyvinyl alcohol embolic microspheres.

[0009] In the above technical scheme, by using two polyvinyl alcohols with different polymerization degrees, after being grafted and modified by a water-soluble crosslinking agent and polymerized and crosslinked with a water-soluble monomer with an ionic functional group, the main chains of the two polyvinyl alcohols interpenetrate to form a blended system, so that the prepared polyvinyl alcohol embolic microspheres have better mechanical properties, which helps the embolic microspheres to maintain structural integrity during transportation and release in the body, reduce drug leakage, and improve the efficiency and safety of drug delivery. At the same time, this interpenetrating network structure can further cause the pore structure and crosslinking density inside the microspheres to change, and during the polymerization process, the hydrophilicity of some polyvinyl alcohol segments with a high degree of grafting with a water-soluble crosslinking agent is low, and they tend to be distributed outside the droplet to form a shell, while the hydrophilicity of some polyethylene segments with a high degree of grafting with a water-soluble crosslinking agent is low, and they tend to be distributed inside the droplet with a water-soluble monomer with an ionic functional group, and form a core after crosslinking polymerization. Therefore, since the surface of the embolic microsphere has a dense polymer spherical shell, the loaded drug exists in the core, which can further slow down the release rate of the drug. By adjusting the molecular weight of two polyvinyl alcohols with different degrees of polymerization, fine control of drug release rate can be achieved.

[0010] In some embodiments of the present application, the mass ratio of high-polymerization degree polyvinyl alcohol to low-polymerization degree polyvinyl alcohol is (1-2):1.

[0011] In the above technical solution, by controlling the mass ratio of high-polymerization degree polyvinyl alcohol to low-polymerization degree polyvinyl alcohol, the interpenetrating network structure and the thickness of the surface polymer spherical shell can be controlled accordingly.

[0012] In some embodiments of the present application, the water-soluble crosslinking agent is selected from at least one of N-(2,2-dimethoxy)-2-methylacrylamide, N-(1-hydroxy-2,2-dimethoxyethyl)-2-acrylamide, N-(2,2-dimethoxy)-2-acrylamide, N-(1-hydroxy-2,2-dimethoxyethyl)-2-methylacrylamide, N-(2,2-dimethoxy)-2-methacrylate, N-(1-hydroxy-2,2-dimethoxyethyl)-2-acrylate, N-(2,2-dimethoxy)-2-acrylate or N-(1-hydroxy-2,2-dimethoxyethyl)-2-methacrylate;

[0013] The amount of the water-soluble cross-linking agent used is 10%-15% of the total mass of the high-polymerization degree polyvinyl alcohol and the low-polymerization degree polyvinyl alcohol.

[0014] In the above technical solution, a monomer with a double bond is selected to graft-modify polyvinyl alcohol. By controlling the amount of the water-soluble cross-linking agent, the degree of graft-modification of polyvinyl alcohol can be correspondingly controlled, thereby affecting the subsequent interpenetrating network structure of the microspheres.

[0015] In some embodiments of the present application, the grafting reaction is carried out in the presence of an acid catalyst, the acid catalyst is selected from at least one of hydrochloric acid, sulfuric acid, nitric acid or p-toluenesulfonic acid, and the mass percentage concentration of the acid catalyst in the reaction system is 5% to 10%.

[0016] In some embodiments of the present application, in the step of preparing the water phase, the amount of the macromolecular monomer solution used is 50% to 70% of the mass of water.

[0017] In some embodiments of the present application, in the step of preparing the aqueous phase, the water-soluble monomer with an ionic functional group is selected from at least one of a carboxylic acid compound or a carboxylate compound with a carboxylate group and a double bond, and a sulfonic acid compound or a sulfonate compound with a sulfonate group and a double bond; the amount of the water-soluble monomer with an ionic functional group is 10% to 20% of the mass of water.

[0018] In some embodiments of the present application, the water-soluble monomer with an ionic functional group is selected from at least one of 2-acrylamido-2-methylpropane sulfonic acid, sodium allyl sulfonate or sodium methacrylic acid.

[0019] In the above technical solution, the amount of the ionic functional groups on the final microspheres can be controlled by controlling the amount of the macromolecular monomer solution and the amount of the water-soluble monomer with ionic functional groups, thereby regulating the drug loading performance of the microspheres.

[0020] In some embodiments of the present application, in the step of preparing the aqueous phase, the initiator is selected from at least one of ammonium persulfate, sodium persulfate or potassium persulfate.

[0021] In the above technical solution, the amount of the initiator used can be 0.5% of the mass of water.

[0022] In some embodiments of the present application, the oil-soluble dispersant is selected from at least one of cellulose acetate butyrate, Span, octylphenol polyoxyethylene ether or oleic acid diethanolamide, and the oil-soluble solvent is selected from at least one of butyl acetate, ethyl acetate, methyl acetate or propyl acetate.

[0023] In some embodiments of the present application, the reverse suspension polymerization reaction comprises: heating the reverse suspension polymerization system to 60-70° C., adding a catalyst, stirring and mixing for 10-30 min, cooling to 40-50° C., and reacting for 3-5 h;

[0024] The catalyst is selected from at least one of tetrahydroxypropylethylenediamine and triethylamine.

[0025] In a second aspect, an embodiment of the present application provides a polyvinyl alcohol embolic microsphere prepared by the above-mentioned preparation method.

[0026] In a third aspect, an embodiment of the present application further provides a use of the above-mentioned polyvinyl alcohol embolic microspheres in the preparation of a drug for treating solid malignant tumors.

[0027] In the above technical solution, the polyvinyl alcohol embolic microspheres have an interpenetrating network structure inside and a dense polymer spherical shell on the surface, so they have excellent mechanical properties and drug sustained-release properties and can be effectively used as a drug delivery carrier. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0029] Figure 1 This is a process flow chart of the method for preparing polyvinyl alcohol embolic microspheres provided in an embodiment of the present application.

[0030] Figure 2 This is an image of the polyvinyl alcohol embolic microspheres prepared in Example 1 of the present application under an optical microscope.

[0031] Figure 3 This is an image of the polyvinyl alcohol embolic microspheres prepared in Example 2 of the present application under an optical microscope.

[0032] Figure 4 This is an image of the polyvinyl alcohol embolic microspheres prepared in Example 3 of the present application under an optical microscope.

[0033] Figure 5 This is an image of the polyvinyl alcohol embolic microspheres prepared in Comparative Example 1 of the present application under an optical microscope.

[0034] Figure 6 This is a drug release curve of the polyvinyl alcohol embolic microspheres prepared in Example 1 of the present application.

[0035] Figure 7 This is a drug release curve of the polyvinyl alcohol embolic microspheres prepared in Example 2 of the present application.

[0036] Figure 8 This is a drug release curve of the polyvinyl alcohol embolic microspheres prepared in Example 3 of the present application.

[0037] Fig. 9This is a drug release curve of the polyvinyl alcohol embolic microspheres prepared in Comparative Example 1 of the present application. DETAILED DESCRIPTION

[0038] Figure 1 This is a process flow chart of the preparation method of polyvinyl alcohol embolic microspheres provided in the embodiment of this application. Figure 1 The method for preparing polyvinyl alcohol embolic microspheres provided in the present application comprises the following steps:

[0039] S110, preparing a macromonomer solution: performing a grafting reaction on high-polymerization degree polyvinyl alcohol, low-polymerization degree polyvinyl alcohol and a water-soluble crosslinking agent in a certain proportion to obtain a macromonomer solution.

[0040] Among them, the degree of polymerization of high-polymerization polyvinyl alcohol is 1700-2600, and the degree of polymerization of low-polymerization polyvinyl alcohol is 300-500. High-polymerization polyvinyl alcohol has a high molecular weight, high tensile strength and wear resistance, and low-polymerization polyvinyl alcohol has a relatively low molecular weight, good toughness and fluidity. The two polyvinyl alcohols with different polymerization degrees are grafted and modified, and after cross-linking polymerization, the main chains of the two polyvinyl alcohols can be interpenetrated to form a blending system.

[0041] In the embodiment of the present application, the high polymerization degree polyvinyl alcohol can be selected from 1788 type (polymerization degree is 1700, molecular weight is 74800, alcoholysis degree is 88%), 2088 type (polymerization degree is 2000, molecular weight is 88000, alcoholysis degree is 88%), 2488 type (polymerization degree is 2400, molecular weight is 105600, alcoholysis degree is 88%), 2688 type (polymerization degree is 2600, molecular weight is 114400, alcoholysis degree is 88%), 1799 (degree of polymerization is 1700, molecular weight is 74800, alcoholysis degree is 99%), 2099 (degree of polymerization is 2000, molecular weight is 88000, alcoholysis degree is 99%), 2499 (degree of polymerization is 2400, molecular weight is 105600, alcoholysis degree is 99%), 2699 (degree of polymerization is 2600, molecular weight is 114400, alcoholysis degree is 99%) polyvinyl alcohol. The low-polymerization degree polyvinyl alcohol can be selected from any one of type 0388 (polymerization degree is 300, molecular weight is 13200, and alcoholysis degree is 88%), type 0588 (polymerization degree is 500, molecular weight is 22000, and alcoholysis degree is 88%), type 0399 (polymerization degree is 300, molecular weight is 13200, and alcoholysis degree is 99%), and type 0599 (polymerization degree is 500, molecular weight is 22000, and alcoholysis degree is 99%).

[0042] It can be understood that the high-polymerization degree polyvinyl alcohol referred to in the embodiments of the present application is defined relative to the low-polymerization degree polyvinyl alcohol, and is not strictly classified according to the degree of polymerization of polyvinyl alcohol in actual application.

[0043] The mass ratio of high-polymerization degree polyvinyl alcohol to low-polymerization degree polyvinyl alcohol is (1-2): 1. For example, the mass ratio of the two can be 1: 1, 1: 2, 2: 1, etc. By controlling the mass ratio of high-polymerization degree polyvinyl alcohol to low-polymerization degree polyvinyl alcohol, the three-dimensional interpenetrating network structure of the final microspheres can be controlled accordingly, thereby regulating the strength and elasticity of the microspheres.

[0044] In the embodiment of the present application, before the grafting reaction with the water-soluble crosslinking agent, the high-polymerization degree polyvinyl alcohol and the low-polymerization degree polyvinyl alcohol need to be heated and dissolved. Preferably, the high-polymerization degree polyvinyl alcohol and the low-polymerization degree polyvinyl alcohol are added to water, heated to 80-95° C., stirred and dissolved to form a uniform mixed solution. Preferably, in the mixed solution, the total mass concentration of the high-polymerization degree polyvinyl alcohol and the low-polymerization degree polyvinyl alcohol is 20wt%.

[0045] The water-soluble crosslinking agent is selected from at least one of N-(2,2-dimethoxy)-2-methyl acrylamide, N-(1-hydroxy-2,2-dimethoxyethyl)-2-acrylamide, N-(2,2-dimethoxy)-2-acrylamide, N-(1-hydroxy-2,2-dimethoxyethyl)-2-methyl acrylamide, N-(2,2-dimethoxy)-2-methyl acrylate, N-(1-hydroxy-2,2-dimethoxyethyl)-2-acrylate, N-(2,2-dimethoxy)-2-acrylate or N-(1-hydroxy-2,2-dimethoxyethyl)-2-methyl acrylate. The amount of the water-soluble crosslinking agent is 10%-15% of the total mass of the high-polymerization degree polyvinyl alcohol and the low-polymerization degree polyvinyl alcohol.

[0046] In the embodiment of the present application, a water-soluble crosslinking agent monomer with a double bond is selected. By controlling the amount added, the degree of grafting on the polyvinyl alcohol main chain can be correspondingly controlled, thereby affecting the distribution of molecular chains in the subsequent polymerization and crosslinking processes, thereby regulating the structure of the embolic microspheres.

[0047] The grafting reaction is carried out in the presence of an acidic catalyst, which may be at least one of hydrochloric acid, sulfuric acid, nitric acid and p-toluenesulfonic acid, and the mass percentage concentration of the acid catalyst in the grafting reaction system is 5% to 10%.

[0048] In the embodiments of the present application, the temperature of the grafting reaction can be 20 to 25° C., and the time can be 10 to 15 hours.

[0049] S120, preparing an aqueous phase: adding a macromolecular monomer solution, a water-soluble monomer with an ionic functional group, and an initiator into water, and mixing them to obtain an aqueous phase.

[0050] Wherein, the amount of the macromolecular monomer solution is 50% to 70% of the mass of water. The water-soluble monomer with ionic functional groups can be selected from at least one of a carboxylic acid compound or a carboxylate compound with a carboxylate radical and a double bond, a sulfonic acid compound or a sulfonate compound with a sulfonate radical and a double bond. As an example, the water-soluble monomer with ionic functional groups can be sodium acrylate, 2-acrylamido-2-methylpropanesulfonic acid, sodium allyl sulfonate or sodium methacrylate sulfonate. The amount of the water-soluble monomer with ionic functional groups is 10% to 20% of the mass of water.

[0051] The initiator can be selected from at least one of ammonium persulfate, sodium persulfate or potassium persulfate, and the amount of the initiator used accounts for 0.5% of the mass of water. Preferably, the initiator is ammonium persulfate.

[0052] In the step of "preparing the aqueous phase", the macromolecular monomer solution, the water-soluble monomer with ionic functional groups and the initiator are mixed in an alkaline environment. Specifically, the macromolecular monomer solution, the water-soluble monomer with ionic functional groups, sodium hydroxide and the initiator are added to water and mixed to obtain an aqueous phase. The amount of sodium hydroxide used is 2% to 5% of the mass of water.

[0053] S130, preparing an oil phase: mixing an oil-soluble dispersant and an oil-soluble solvent to obtain an oil phase.

[0054] Among them, the oil-soluble dispersant can be selected from at least one of cellulose acetate butyrate, Span, octylphenol polyoxyethylene ether or oleic acid diethanolamide, and the oil-soluble solvent can be selected from at least one of butyl acetate, ethyl acetate, methyl acetate or propyl acetate.

[0055] Specifically, the method may include: dissolving an oil-soluble dispersant in an oil-soluble solvent, stirring and dissolving at 40 to 70° C. to obtain an oil phase, wherein the mass concentration of the oil-soluble dispersant is 2% to 3%.

[0056] S140, reverse suspension polymerization: adding the water phase into the oil phase to form an oil-in-water reverse suspension polymerization system, and performing reverse suspension polymerization to obtain polyvinyl alcohol embolic microspheres.

[0057] Specifically, the process may include adding the water phase to the oil phase under stirring to form an oil-in-water reverse suspension polymerization system, heating the system to 60-70°C, adding a catalyst thereto, and maintaining stirring at the above temperature for 10-30 minutes. Lowering the temperature to 40-50°C, stirring continuously for 3-5 hours, and then shutting down the equipment to terminate the reaction.

[0058] Wherein, the catalyst can be selected from tetrahydroxypropylethylenediamine and triethylamine.

[0059] In the examples of the present application, the particle size of the prepared polyvinyl alcohol embolic microspheres is 100 to 300 μm.

[0060] It is understandable that after the reverse suspension polymerization reaction is completed, washing, purification and screening steps are also included. Specifically, it may include: after the reaction is completed, the reaction system is allowed to stand for 10 to 30 minutes to allow stratification, the upper oil phase is removed, and the lower precipitate is collected. The microspheres are washed and purified with ultrapure water, and the polyvinyl alcohol embolic microspheres with a particle size of 100 to 300 μm are screened using a stainless steel metal sieve.

[0061] In this application, two polyvinyl alcohols with different polymerization degrees are used as skeleton materials. After being grafted and modified by a water-soluble crosslinking agent, the main chains of polyvinyl alcohols with different polymerization degrees interpenetrate to form a blended system, and then polymerize and crosslink with water-soluble monomers with ionic functional groups to form an interpenetrating network structure, so that the entire polyvinyl alcohol embolic microspheres have better mechanical properties, which helps the microspheres to maintain structural integrity during transportation and release in the body, reduce drug leakage, and improve the efficiency and safety of drug delivery. At the same time, affected by the interpenetrating structure, the pore structure and crosslinking density of the microspheres will change, and it is better than the different polymerization degrees of the two polyvinyl alcohols, resulting in different grafting degrees and subsequent crosslinking degrees. A layer of dense polymer spherical shell is formed on the surface of the polyvinyl alcohol embolic microspheres, which can slow down the release rate of the drug. Therefore, by adjusting the molecular weight of the two polyvinyl alcohols, fine control of the drug release rate can be achieved.

[0062] The embodiment of the present application also provides a polyvinyl alcohol embolic microsphere prepared by the above-mentioned preparation method, and the polyvinyl alcohol embolic microsphere can be used as a drug-loaded microsphere for drug delivery to treat solid malignant tumors.

[0063] The polyvinyl alcohol embolic microspheres have ionic functional groups, and thus can load drugs through positive and negative electrical attraction. Due to their excellent mechanical properties and the presence of a dense polymer shell on the surface of the polyvinyl alcohol embolic microspheres, the polyvinyl alcohol embolic microspheres provided in this application have better drug sustained-release performance than the same types of microspheres on the market.

[0064] Example 1

[0065] This embodiment provides a polyvinyl alcohol embolic microsphere, and the preparation method thereof comprises the following steps:

[0066] (1) Preparation of macromonomer solution

[0067] High-polymerization degree polyvinyl alcohol (1788: polymerization degree of 1700, alcoholysis degree of 88%, molecular weight of 74800) and low-polymerization degree polyvinyl alcohol (0588: polymerization degree of 500, alcoholysis degree of 88%, molecular weight of 22000) are mixed and added to water in a mass ratio of 2:1, wherein the total mass of high-polymerization degree polyvinyl alcohol and low-polymerization degree polyvinyl alcohol is 20wt% of water, and the temperature is raised to 80℃-95℃, and stirred and dissolved to form a uniform solution. Then, a water-soluble crosslinking agent N-(2,2-dimethoxy)-2-methylacrylamide is added, wherein the amount of the water-soluble crosslinking agent is 15wt% of the polyvinyl alcohol; after stirring evenly, an acid catalyst toluenesulfonic acid is added, wherein the amount of the acid catalyst is 25wt% of the polyvinyl alcohol, and the temperature is lowered to 20-25℃ and stirred for 10-15h to obtain a macromolecular monomer solution.

[0068] (2) Prepare the aqueous phase

[0069] The macromonomer solution, 2-acrylamide-2-methylpropanesulfonic acid, sodium hydroxide and ammonium persulfate are added to water, dissolved and stirred evenly to obtain an aqueous phase, wherein the mass percentage of the macromonomer solution in water is 50wt%, the mass percentage of 2-acrylamide-2-methylpropanesulfonic acid in water is 10wt%, the mass percentage of sodium hydroxide in water is 2wt%, and the mass percentage of ammonium persulfate in water is 0.5wt%.

[0070] (3) Prepare the oil phase

[0071] Cellulose acetate butyrate was dissolved in butyl acetate solution, and the mixture was stirred and dissolved at 70° C. to form a uniform solution to obtain an oil phase, wherein the mass percentage of cellulose acetate butyrate in the oil phase was 3 wt %.

[0072] (4) Inverse suspension polymerization

[0073] Under the above conditions, set the stirring rate to 200rpm, and drop the above water phase into the oil phase to form an oil-in-water reverse suspension polymerization system. After the dropwise addition is completed, stir for 30 minutes to make the system evenly dispersed, heat to 70°C, add the catalyst tetramethylethylenediamine, and keep stirring at the above temperature for 30 minutes. Lower the temperature to 40°C, continue stirring for 3-5 hours, turn off the equipment, and end the reaction.

[0074] After the reaction is completed, the reaction system is allowed to stand for 10-30 minutes to separate the layers, the upper oil phase is removed, and the lower precipitate is collected. The microspheres are washed and purified with ultrapure water. The polyvinyl alcohol embolization microspheres with a particle size of 100-300 μm are obtained by sieving with a stainless steel metal sieve.

[0075] Example 2

[0076] This embodiment provides a polyvinyl alcohol embolic microsphere, and its preparation process is different from the preparation process of Example 1 only in that: in step (1), the mass ratio of high-polymerization degree polyvinyl alcohol to low-polymerization degree polyvinyl alcohol is 1:1, wherein the degree of polymerization of the high-polymerization degree polyvinyl alcohol is 2299, and the degree of polymerization of the low-polymerization degree polyvinyl alcohol is 300.

[0077] Example 3

[0078] This embodiment provides a polyvinyl alcohol embolic microsphere, and its preparation process is different from the preparation process of Example 1 only in that: in step (1), the mass ratio of high-polymerization degree polyvinyl alcohol to low-polymerization degree polyvinyl alcohol is 1:2, wherein the degree of polymerization of the high-polymerization degree polyvinyl alcohol is 2600, and the degree of polymerization of the low-polymerization degree polyvinyl alcohol is 400.

[0079] Comparative Example 1

[0080] This comparative example provides a polyvinyl alcohol embolic microsphere, and the preparation process thereof is different from that of Example 1 only in that in step (1), high-polymerization degree polyvinyl alcohol and low-polymerization degree polyvinyl alcohol are replaced with only high-polymerization degree polyvinyl alcohol.

[0081] Comparative Example 2

[0082] This comparative example provides a polyvinyl alcohol embolic microsphere, and the preparation process thereof is different from that of Example 1 only in that in step (1), high-polymerization degree polyvinyl alcohol and low-polymerization degree polyvinyl alcohol are replaced with only low-polymerization degree polyvinyl alcohol.

[0083] Some of the reaction conditions in the above examples and comparative examples are shown in Table 1.

[0084] Table 1 Partial reaction conditions of Examples and Comparative Examples

[0085]

[0086] Performance Testing

[0087] The performance of the polyvinyl alcohol embolic microspheres prepared in the above examples and comparative examples was tested, and the specific testing method is as follows: Among them, the commercially available product is UniPearls microspheres.

[0088] 1. Observation of microsphere appearance

[0089] Take 1 mL of polyvinyl alcohol embolization microspheres, dry the surface water with filter paper, spread them on a glass slide, and observe them under an optical microscope.

[0090] 2. Physical performance test

[0091] Take a single developed microsphere in pure water and place it in the center of a glass slide. Use a Beijing Weixun TA.XT Plus C texture analyzer for strength analysis. Select the Hold Compression mode for testing. Set the downward pressure to 50%, collect the strength and elasticity, and take the average of three times.

[0092] 3. Drug release performance test

[0093] Prepare 20 mg / mL doxorubicin hydrochloride solution, take 1 mL of polyvinyl alcohol embolic microspheres, dry the surface moisture with filter paper, put them in a vial, add 2 mL of the solution to the vial, shake for 30 minutes, then draw the supernatant, use an ultraviolet spectrophotometer to measure the absorbance at 233 nm, and substitute it into the drug concentration standard curve to calculate the drug loading amount.

[0094] Place the drug-loaded microspheres into a drug release bag, place the drug release bag containing the drug-loaded microspheres into a conical flask, add 100mL of 0.9% NaCl into the flask, put in a rotor, seal the conical flask and place it in a 37°C constant temperature stirring water bath for release, take 5mL of release solution with a pipette after a period of time, and add fresh 0.9% NaCl (5mL). Sample the solution in the conical flask on time to detect the absorbance, substitute it into the standard curve for calculation, calculate the cumulative release rate of the drug, record the data and draw a release curve.

[0095] The cumulative release rate calculation formula is as follows:

[0096]

[0097] Where, Q is the cumulative release rate of the drug (%), M D is the mass of the drug loaded, n is the number of times the drug is taken, C n is the concentration of the drug sample taken for the nth time, V is the total volume of the release solution, C i is the concentration of the drug sample taken for the i-th time, V i is the sample volume of the i-th sampling, C0 and V0 are both 0.

[0098] Results Analysis

[0099] 1. Physical properties and appearance

[0100] The strength and elasticity test results of the embodiments, comparative examples and commercially available products are shown in Table 2:

[0101] Table 2 Physical properties of polyvinyl alcohol embolic microspheres

[0102]

[0103]

[0104] from Figure 2 , Figure 3 , Figure 4 and Figure 5 It can be seen from the comparison that the polyvinyl alcohol embolic microspheres prepared in Examples 1-3 have a regular morphology and a dense polymer film on the surface. Combined with the performance test results in Table 2, it can be seen that the polyvinyl alcohol embolic microspheres prepared by blending and modifying high-polymerization degree and low-polymerization degree polyvinyl alcohol in corresponding proportions have good strength and elasticity due to the interpenetrating network structure inside the microspheres. Among them, the polyvinyl alcohol embolic microspheres prepared in Example 2 have better elasticity and strength than those of Comparative Example 1, Comparative Example 2 and commercially available products.

[0105] 2. Drug release performance

[0106] The drug loading of polyvinyl alcohol embolic microspheres is shown in Table 3. It can be seen from Table 3 that the drug loading of polyvinyl alcohol embolic microspheres in Example and Comparative Example 1 is maintained at the same level, while the drug loading of Comparative Example 2 and the commercially available product is relatively low.

[0107] Table 3 Drug loading of polyvinyl alcohol embolic microspheres

[0108] Experimental groups Drug loading (mg) Example 1 39.4 Example 2 39.5 Example 3 39.3 Comparative Example 1 39.5 Comparative Example 2 27.6 Commercially available products 32.8

[0109] Figures 6 to 8 The drug release curves of polyvinyl alcohol embolic microspheres in Examples 1-3 and Comparative Example 1 are shown in FIG. Figure 6 , 7 8, it can be seen that the polyvinyl alcohol embolic microspheres prepared by blending and modifying high-polymerization degree and low-polymerization degree polyvinyl alcohol in corresponding proportions in Examples 1, 2, and 3 all reached the maximum release amount at 19 to 20 days. Fig. 9 It can be seen that the polyvinyl alcohol embolic microspheres prepared by using a single polyvinyl alcohol for synthesis in Comparative Example 1 reached the maximum release amount on the 9th day. It can be seen that the polyvinyl alcohol embolic microspheres provided by the present invention are prepared by blending and modifying polyvinyl alcohols with high polymerization degree and low polymerization degree according to corresponding proportions. The performance of the polyvinyl alcohol embolic microspheres prepared by using a single polyvinyl alcohol for synthesis in terms of the overall release cycle is much better than that of the polyvinyl alcohol embolic microspheres prepared by using a single polyvinyl alcohol for synthesis.

[0110] At the same time, the polyvinyl alcohol embolic microspheres provided by the present invention have a dense polymer shell on their surface, as follows Figure 6 , 7 As shown in Figures 8, after the initial release, the release rate remained stable during the release process from day 1 to day 16, which greatly improved the instability of the initial drug release and well controlled the exchange rate between the microsphere-loaded drug and the external ions.

[0111] The embodiments described above are part of the embodiments of the present application, rather than all of the embodiments. The detailed description of the embodiments of the present application is not intended to limit the scope of the present application for protection, but merely represents the selected embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present application.

Claims

1. A method for preparing polyvinyl alcohol embolic microspheres, characterized in that: The steps include: Preparing a macromolecular monomer solution: performing a grafting reaction on high-polymerization degree polyvinyl alcohol, low-polymerization degree polyvinyl alcohol and a water-soluble crosslinking agent in a certain proportion to obtain a macromolecular monomer solution; Preparing an aqueous phase: adding the macromolecular monomer solution, the water-soluble monomer with ionic functional groups and the initiator into water, and mixing them to obtain an aqueous phase; Preparing the oil phase: mixing the oil-soluble dispersant and the oil-soluble solvent to obtain the oil phase; Reverse suspension polymerization reaction: adding the water phase into the oil phase to form a water-in-oil reverse suspension polymerization system, and performing reverse suspension polymerization reaction to obtain the polyvinyl alcohol embolic microspheres; The degree of polymerization of the high-polymerization degree polyvinyl alcohol is 1700-2600, and the degree of polymerization of the low-polymerization degree polyvinyl alcohol is 300-500.

2. The preparation method according to claim 1, characterized in that: The mass ratio of the high-polymerization degree polyvinyl alcohol to the low-polymerization degree polyvinyl alcohol is (1-2):

1.

3. The preparation method according to claim 1, characterized in that: The water-soluble crosslinking agent is selected from at least one of N-(2,2-dimethoxy)-2-methylacrylamide, N-(1-hydroxy-2,2-dimethoxyethyl)-2-acrylamide, N-(2,2-dimethoxy)-2-acrylamide, N-(1-hydroxy-2,2-dimethoxyethyl)-2-methylacrylamide, N-(2,2-dimethoxy)-2-methylacrylate, N-(1-hydroxy-2,2-dimethoxyethyl)-2-acrylate, N-(2,2-dimethoxy)-2-acrylate or N-(1-hydroxy-2,2-dimethoxyethyl)-2-methylacrylate; The amount of the water-soluble cross-linking agent used is 10% to 15% of the total mass of the high-polymerization degree polyvinyl alcohol and the low-polymerization degree polyvinyl alcohol.

4. The preparation method according to claim 1, characterized in that: In the step of preparing the water phase, the amount of the macromolecular monomer solution is 50% to 70% of the mass of the water.

5. The preparation method according to claim 1, characterized in that: In the step of preparing the aqueous phase, the water-soluble monomer with an ionic functional group is selected from at least one of a carboxylic acid compound or a carboxylate compound with a carboxylate group and a double bond, and a sulfonic acid compound or a sulfonate compound with a sulfonate group and a double bond; The amount of the water-soluble monomer with ionic functional groups is 10% to 20% of the mass of the water.

6. The preparation method according to claim 5, characterized in that: The water-soluble monomer with ionic functional groups is selected from at least one of 2-acrylamido-2-methylpropanesulfonic acid, sodium allyl sulfonate or sodium methacrylic acid.

7. The preparation method according to claim 1, characterized in that: The oil-soluble dispersant is selected from at least one of cellulose acetate butyrate, Span, octylphenol polyoxyethylene ether or oleic acid diethanolamide; The oil-soluble solvent is selected from at least one of butyl acetate, ethyl acetate, methyl acetate or propyl acetate.

8. The preparation method according to claim 1, characterized in that: The reverse suspension polymerization reaction comprises: heating the reverse suspension polymerization system to 60-70° C., adding a catalyst, stirring and mixing for 10-30 minutes, cooling to 40-50° C., and reacting for 3-5 hours; The catalyst is selected from at least one of tetrahydroxypropylethylenediamine and triethylamine.

9. A polyvinyl alcohol embolic microsphere, characterized in that: The method is prepared according to any one of claims 1 to 8.

10. Use of the polyvinyl alcohol embolic microspheres as claimed in claim 9 in the preparation of a drug for treating solid malignant tumors.